PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsLung cancer gene test approved as 'companion diagnostic'

BioNews

Lung cancer gene test approved as 'companion diagnostic'

Published 17 May 2013 posted in News and appears in BioNews 705

Author

Dr Jamie Heather

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The US medicines regulator, the Food and Drug Administration, has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib...

The US medicines regulator, the Food and Drug
Administration (FDA), has approved a genetic test to help doctors select
suitable lung cancer patients to be treated with the drug erlotinib (sold as Tarceva).

The diagnostic from Roche is the first licensed test for variants
of the EGFR gene, which encodes the protein that erlotinib targets.

Dr Hal Barron, head of global product development at
Roche says that 'ten to 30 percent of people worldwide with lung cancer have
tumours that test positive for certain EGFR mutations'.

The test will be used to check whether patients with
advanced, metastatic cancer — where the cancerous cells have spread to other
parts of the body — have one of these mutations. If they do, then they are more likely to benefit from erlotinib
in place of standard chemotherapy.

The EURTAC clinical trial validated this approach. In
the study, patients with EGFR mutations treated with erlotinib lived for over ten months without their getting worse. In comparison, patients given standard
chemotherapy lived without disease progression for only five months.

These non-small cell lung cancers (NSCLC) account for the
majority of lung cancers, which themselves account for the majority of the
cancer-related deaths. Personalised medicine regimes such as this aim to tailor
drug courses to those patients for whom the drugs are most likely to be
effective. It is hoped that this will provide better outcomes for patients,
while using restricted healthcare funds more cost-effectively.

Erlotinib has been licensed in the UK and elsewhere in
Europe as first-line treatment of NSCLC in patients harbouring appropriate
EFGR mutations since 2012, after the EURTAC trial showed it to be effective. It
is also indicated as a potential second-line treatment where previous
chemotherapy courses have failed.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 September 2014 • 2 minutes read

Prototype lung cancer breath test checks for gene mutations

by Dr Antony Starza-Allen

Scientists have shown that minimal genetic changes can be detected in vapour containing cells engineered to replicate early stage lung cancer....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
29 November 2013 • 2 minutes read

23andMe's genetics screening service sold in violation of regulations, says FDA

by Ruth Saunders

The US Food and Drug Administration has ordered 23andMe to 'immediately discontinue' its Personal Genome Service after failing to undergo proper agency approval for its marketing claims...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 May 2013 • 2 minutes read

Genetic testing programme for cancer risk launched

by Dr Shanya Sivakumaran

A genetic testing programme that will look for nearly 100 cancer risk genes has been launched, in the hope that genetic tests will become routine for cancer patients across the UK....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 March 2013 • 3 minutes read

Consumer genetics firm 23andMe seeks regulatory approval for disease risk tests

by Ruth Saunders

23andMe, a US-based personal genomics company, has sought regulatory approval from the Food and Drug Administration for seven of its genetic tests....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 February 2013 • 3 minutes read

Genetic tests that improve drug effectiveness are going neglected, warns expert

by James Brooks

Genetic tests that could greatly improve the effectiveness of drug therapy for a wide variety of conditions are being underused or ignored, a leading expert says...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 November 2012 • 2 minutes read

Gene mutation melanoma drug recommended for NHS use

by Maria Sheppard

A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 December 2011 • 2 minutes read

Personalised medicine patents disputed at US Supreme Court

by Nishat Hyder

A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning 'personalised medicine' industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Turkish womb transplant patient miscarries

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856